Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
A phase 2 trial of BH3 profiling in Oesophageal cancer and Oesophageal and junctional adenocarcinoma, run by National Cancer Institute (NCI), recorded as terminated on the registry.
Overview
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy is a phase 2 interventional study registered as NCT03223662 by National Cancer Institute (NCI), with 2 participants recorded, started 2017-10-31 and due to reach its primary completion in 2018-07-27. Interventions recorded: Chemoradiotherapy, Esophagectomy. Conditions recorded: Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma.
Linked to the technology BH3 profiling because the registry's title names it ("bh3 profiling") and Oesophageal cancer and Oesophageal and junctional adenocarcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
- TrialPhase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
- TrialClinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
Shares Oesophageal and junctional adenocarcinoma and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
- TrialA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
- TrialSingle Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer
Shares Oesophageal cancer and the tag pipeline.
- TrialA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Shares Oesophageal cancer and the tag pipeline.